SEC Form 4 · accession 0000899243-18-024819
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John G. Aunins
Officer — See Remarks
Period of report
May 15, 2018
Accepted (ET)
Sep 19, 2018 · 9:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF2 | May 15, 2018 | S | 14,279 | $8.0818 | D | 146,648 | D | |
| COMMON STOCKF3 | Aug 15, 2018 | S | 14,279 | $7.5684 | D | 132,369 | D | |
| COMMON STOCKF4 | Sep 17, 2018 | S | 14,279 | $7.2747 | D | 118,090 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $7.8800 to $8.1400. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This filing is being reported late due to an inadvertent administrative error.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $7.2500 to $7.7600. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This filing is being reported late due to an inadvertent administrative error.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $7.0914 to $7.5600. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks
Chief Technology Officer and EVP